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Abstract
Background: Around 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and
such patients have considerable unmet need. Identifying effective therapy is important but to what extent
fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current
analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they
differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.
Methods: The British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83
centres 2012–2017. Clinical data, and information from patients was collected (including research criteria for
fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the
whole population and the sub-group which met fibromyalgia criteria.
Results: One thousand three hundred thirty-eight participants were included of whom 23% met research criteria
for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily
axial (n = 347) and a smaller cluster (n = 32) with axial and peripheral disease, and in both groups more than half of
members met criteria for fibromyalgia. The remaining two clusters (n = 437, n = 462) had overall less severe disease
however the one which showed greater disease activity and poorer quality of life had a higher proportion meeting
fibromyalgia criteria (16% v. 4%). Within those meeting fibromyalgia criteria there were three clusters. The two main
groups were defined by level of symptom severity with a smaller third cluster noted to have high average swollen
and tender joint counts and high levels of comorbidity.
Conclusions: The major feature defining clusters with a high proportion of persons meeting criteria for
fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high
disease activity also show moderately high prevalence. Management may be most successful with pharmacologic
therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such
patients.
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Background
Fibromyalgia is common as a co-morbidity in inflamma-
tory arthritis. A recent meta-analysis estimated the
prevalence as 21% (95% CI 17, 25) in rheumatoid arth-
ritis (RA) across 25 studies, 13% (95% CI 7, 19) in axial
spondyloarthritis (axSpA) across eight studies and 18%
(95% CI 13, 23) in psoriatic arthritis across six studies
[1]. There has been specific interest in the
co-occurrence of fibromyalgia and axSpA for two rea-
sons. The first is a result of a United States Food and
Drug Administration Arthritis Advisory Committee
meeting in 2013 which considered the case for expand-
ing the use of Tumour Necrosis Factor inhibition (TNFi)
therapy from ankylosing spondylitis to non-radiographic
axSpA. The application was not approved partly because
of concerns about the inappropriate use of such therapy
for conditions such as back pain and fibromyalgia in the
presence of minor magnetic resonance imaging (MRI)
changes or positive HLA-B27 results [2]. The second
reason is around understanding the mechanisms of de-
velopment of fibromyalgia. One hypothesis is that per-
ipheral nociception, if sustained such as in axSpA, could
in the context of an individual susceptible to its develop-
ment, lead to central sensitisation and the development
of fibromyalgia . An alternative possibility is that high
levels of disease activity, and consequent pain, poor
function and impact on quality of life including work,
lead to emotional distress which itself has been shown
to increase the risk of fibromyalgia. [3].
The British Society for Rheumatology Biologics Regis-
ter (BSRBR-AS) of patients with axSpA is by far the lar-
gest study to have examined fibromyalgia as a
comorbidity in this condition. In analysis of 1504 pa-
tients, it reported that 20.7% met the 2011 research cri-
teria for fibromyalgia [4, 5]. Those with co-morbid
fibromyalgia had high levels of unmet need; this in-
cluded substantially worse disease activity scores, func-
tion, global status (all measured using Bath indices) and
quality of life [4], findings which have been consistent
across studies [6, 7]. If persons with poorly controlled
disease are more likely to fulfill criteria for fibromyalgia
through the process of central sensitisation, then man-
agement should focus on reducing disease activity asso-
ciated with axSpA. Alternatively if the co-morbid
fibromyalgia-like symptoms are unrelated to disease ac-
tivity and arise through distinct mechanisms, then man-
agement should focus on the fibromyalgia (in addition
to any management necessary for axSpA).
In this analysis, using BSRBR-AS, we aimed to estab-
lish if distinct clusters of patients with axSpA exist, and
if so to a) ascertain whether such clusters exhibit im-
portant differences in the prevalence of fibromyalgia and
b) determine features of the clusters which exhibit a
high prevalence of fibromyalgia.
Methods
BSRBR-AS is a prospective cohort study which recruited
biologic-therapy naïve patients from across Great Britain
fulfilling Assessment of SpondyloaArthritis international
Society (ASAS) criteria for axSpA [8]. Recruitment for
the study took place between December 2012 and De-
cember 2017 across 83 secondary care rheumatology
centres. Initially only those fulfilling the imaging ASAS
criteria were eligible for inclusion, however from No-
vember 2014 those meeting the clinical arm were also
eligible. The full protocol has been published previously
[9]. Patients were recruited to one of two sub-cohorts:
those about to commence a biologic therapy (adalimu-
mab, etanercept or certolizumab pegol) and those con-
tinuing on non-biologic therapy. The biologic cohort
was followed up at 3 months and 6months, and both co-
horts were followed-up at 12 months and yearly there-
after up to a maximum of 5 years. If a patient in the
non-biologic cohort commenced biologic therapy they
switched sub-cohort and started a new follow-up
schedule.
Clinical data collected during recruitment and
follow-up appointments included: the presence of
extra-spinal manifestations (history of uveitis, psoriasis,
inflammatory bowel disease (IBD), peripheral joint in-
volvement, dactylitis and enthesitis), history of comor-
bidities and physician-assessed swollen and tender joint
count (40 and 44 joints respectively), and Bath metrol-
ogy index (BASMI). In addition to clinical data, patient
reported questionnaires were mailed at the same time
and included validated instruments assessing, among
others: Bath indices of disease activity (BASDAI), func-
tion (BASFI), global assessment (BAS-G), mental health
(Hospital Anxiety and Depression Scale (HADs) (anxiety
and depression subscales each scored 0–21) [10]), fatigue
(Chalder fatigue scale, scored 0–11 [11]) and sleep dis-
turbance (Jenkins Sleep Evaluation Questionnaire,
scored 0–20 [12]). From August 2015, the patient re-
ported questionnaire included the 2011 modification of
the 2010 ACR criteria for fibromyalgia [5]. As the aim of
the current analysis was to identify discrete clusters
within the axSpA population, in which the prevalence of
fibromyalgia would be calculated; only participants who
had completed a questionnaire after August 2015 were
eligible for inclusion and amongst those who had, the
first completion of the fibromyalgia research criteria was
used as the time-point for data included in the current
analysis.
Cluster analysis classifies individuals into groups (clus-
ters) which optimise homogeneity within groups and
heterogeneity between groups, based on a selection of
pre-defined characteristics (clustering variables). The
groups formed are highly dependent on the variables of-
fered for clustering, therefore, the choice of these is
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ideally underpinned by empirical evidence. As the num-
ber of clusters is not known prior to analysis, a common
approach is to determine the optimal clustering solution
in one sample and to validate in a second sample. The
choice of variables for the current analysis was deter-
mined through simple descriptive statistics (t-tests) in
which those factors associated with fibromyalgia at p ≤
0.05 were considered important. To mitigate the effects
of any differences in measurement scale used across
clustering variables, and to adjust for non-normal distri-
bution; each variable was standardised through z-score
transformation. Prior to analysis, the eligible BSRBR-AS
population was split into two equal-sized samples in
which the optimal clustering solution was developed
(Sample A) and then validated (Sample B). A three-stage
approach was chosen:
Stage 1 - An agglomerative hierarchical cluster analysis
was applied to Sample A using the Euclidean distance
measure and weighted-average linkage method. The
optimal number of cluster solutions was determined
through consultation of the dendrogram and agglomer-
ation schedule.
Stage 2 - The optimal solution from stage 1 was
validated in Sample B using K-means clustering. The
characteristics of each cluster was assessed and com-
pared against those identified by the hierarchical ana-
lysis. Where the clustering solutions appeared identical,
or near-identical, the solution was considered validated.
Stage 3 - Once the optimal solution was determined
and validated (stages 1 & 2) the K-means clustering
was conducted once more within Samples A and B
combined to identify the final groupings of all partici-
pants. These clusters were examined in terms of both
the clustering variables used (mean and standard devia-
tions of non-transformed values) and the prevalence of
fibromyalgia (or more specifically meeting research cri-
teria for fibromyalgia).
On completion of the clustering procedure, the final
clusters were examined to explore differences in both
clinician and patient-reported factors. Demographic
characteristics included: age, age at symptom onset, gen-
der, smoking and alcohol use, while clinical factors in-
cluded: classification criteria met, treatments prescribed
and spinal mobility (BASMI: scored 0 (least) - 10 (most)
severe [13]). Patient reported measures of health, from
questionnaires, included the BASDAI, BASFI and
BAS-G: all scored 0 (least) - 10 (most) severe [14–16])
and spinal pain (scored 0 (least) - 10 (most) severe).
Quality of life was assessed by the Ankylosing Spondyl-
itis Quality of Life Index (ASQoL: scored 0 (good) to 18
(poor) [17]) and the short form 12 (scored 0 (poor) to
100 (best) [18]). Participants were asked to report
co-morbidities including: myocardial infarction, unstable
angina, congestive heart failure, stroke, hypertension,
diabetes, asthma, chronic bronchitis/emphysema, peptic
ulcer, liver disease, renal disease, tuberculosis, demyelin-
ation, depression and cancer. This allowed a
co-morbidity “count” to be derived. Lastly, employment
status was assessed by the Work Productivity and Activ-
ity Impairment scale (WPAI:SHP) to give an indication
of work absence (absenteeism), impairment in
work-productivity (presenteeism), overall work and
non-work activity impairment (all scored as 0–100%
[19]). From the information collected, the Ankylosing
Spondylitis Disease Activity Scale (ASDAS) was calcu-
lated using the measure of CRP (preferentially) or ESR
closest to the patient completed questionnaire used, pro-
vided it was within 90 days [20]. In addition to calculat-
ing the proportion of participants within each cluster
meeting criteria for fibromyalgia, the sub-scales of the
criteria, namely the Widespread Pain Index (WPI, score
0–19) and Symptom Severity Score (SSS, score 0–12)
could be calculated. Differences were assessed using
chi-square or t-tests as appropriate and results are given
as proportions or means (with 95% Confidence Inter-
vals). To determine if similar clusters exist within the
subgroup of participants meeting research criteria for
fibromyalgia, this subgroup was split into two
equal-sized samples (C and D) and the entire clustering
process described above was repeated.
All analysis was conducted on the August 2017 dataset
using STATA (StataCorp LP version 15.0).
Results
In total 1338 participants were eligible for the current
analysis of whom 65% were male, with a median age of
49 years, and median time since symptom onset of 18
years, and 36% had been recruited to the biologic cohort
of the study. Of those tested, 79% were HLA-B27 posi-
tive. Most participants (64.6%) met the modified New
York (mNY) criteria for ankylosing spondylitis, a further
29.7% fulfilled the ASAS imaging criteria for axSpA but
not mNY, while 5.7% only met ASAS clinical criteria for
axSpA. At the time when first completing research cri-
teria for fibromyalgia, 23% (n = 307) were classified posi-
tive. Prior to further analysis, the study population was
randomly split in two equal sized groups.
Factors significantly associated with meeting fibro-
myalgia research criteria were identified and were eli-
gible to be used in the cluster analysis. Where an eligible
variable was strongly related to another eligible variable,
only the factor with the strongest relationship to fibro-
myalgia was used for clustering. The final variable group
used for clustering was: number of extra-spinal manifest-
ation and co-morbidity count, swollen joint count,
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tender joint count, anxiety, depression, fatigue and sleep
disturbance.
The results of the hierarchical analysis in Sample A in-
dicated the presence of 4 distinct clusters which were
validated in Sample B with the K-means analyses. Differ-
ences in the clustering factors across each of the 4 clus-
ters for samples A and B combined are detailed in
Table 1 and Fig. 1. There was one small cluster (Cluster
1) with 32 subjects. It was characterised by high scores
or levels across all clustering variables and amongst par-
ticipants in this cluster there was a very high proportion
of participants who met research criteria for fibromyal-
gia (53%). The remaining clusters were of roughly equal
size (varying between 347 and 462 subjects). Cluster 2
was characterised by few extra-spinal manifestations and
comorbidities, low number of tender and swollen joints
but high levels of anxiety, depression, fatigue and sleep
disturbance. This cluster also had a very high proportion
meeting research criteria for fibromyalgia (54%). Partici-
pants classified in Cluster 3 had few extra-spinal mani-
festations or comorbidities, a low number of tender and
swollen joints low levels of anxiety, depression, fatigue
and sleep disturbance. There was a low proportion meet-
ing research criteria for fibromyalgia (4%). Finally
Cluster 4 was characterised by few extra-spinal manifes-
tations or comorbidities, a low number of tender and
swollen joints, low levels of anxiety, depression and
fatigue, but moderate sleep disturbance. There was a
moderate proportion meeting research criteria for fibro-
myalgia (16%).
Examining factors which were not used in the cluster-
ing (Table 2), it is notable that the members of Clusters
1 and 2, with more than half meeting criteria for fibro-
myalgia, had markedly worse axSpA disease activity,
function, global status, spinal pain, poorer mental and
physical health. Both clusters had mean ASDAS values
in the “very high disease activity” range. (i.e. > 3.5). Qual-
ity of Life and work impact were also worst in Clusters 1
and 2, with intermediate levels in Cluster 4 in compari-
son to Cluster 3. Clusters 1 and 2 were the most likely
to be receiving biologic therapy (31 and 39% respect-
ively) followed by Cluster 4 (24%) and Cluster 3 (14%).
There were approximately double the proportion of
smokers in Clusters 1 and 2 (25 and 29% respectively)
compared to Clusters 3 and 4 (13 and 14%), however in
contrast, more had given up alcohol (28 and 28% v. 10
and 14%). Cluster 1 was distinguished by having a much
higher proportion of female members (59%) than any
other cluster (30–40%).
Participants meeting research criteria for fibromyalgia
were split into two samples (C and D). The results of the
hierarchical analysis on Sample C indicated that there
were three distinct clusters which was validated in the
K-means analysis using Sample D. The 3 cluster solution
using both Samples C and D combined is shown in
Table 3. Cluster 1 was small (n = 17) with members scor-
ing very highly on tender and swollen joints, anxiety, de-
pression, fatigue and sleep problems and consequently
had high pain and symptom severity scores on the fibro-
myalgia research criteria. This cluster was predominantly
female (77%), in contrast to the other clusters which had
40–48% female members. Cluster 2 was larger (n = 157),
with average characteristics very similar to Cluster 1 ex-
cept that almost all members had no swollen or tender
joint and had lower levels of co-morbidities and
extra-spinal manifestations. Nevertheless the WPI and
SSS were very similar between Clusters 1 and 2. In con-
trast, subjects in Cluster 3 (n = 120) scored lower across
Table 1 Clustering variables across clusters (total population) and proportion meeting research criteria for fibromyalgia
N Cluster 1 Cluster 2 Cluster 3 Cluster 4
32 347 427 462
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Clustering Factors
Extra-spinal manifestation & comorbidity count 3.3 (2.7, 3.9) 1.3 (1.1, 1.4) 0.7 (0.6, 0.8) 1.2 (1.1,1.3)
Swollen joint count 8.1 (5.5, 10.7) 0.1 (0.03, 0.2) 0.05 (0.01, 0.1) 0.1 (0.05, 0.13)
Tender joint count 14.3 (11.2, 17.3) 0.4 (0.2, 0.5) 0.2 (0.1, 0.3) 0.4 (0.3, 0.6)
Anxiety score 10.5 (8.6, 12.5) 12.2 (11.8, 12.5) 3.6 (3.4, 3.9) 4.5 (4.2, 4.7)
Depression score 9.2 (7.6, 10.8) 10.3 (10.0, 10.7) 2.2 (2.0, 2.4) 5.2 (5.0, 5.5)
Fatigue score 7.1 (5.9, 8.3) 8.0 (7.7, 8.3) 0.9 (0.8, 1.1) 3.2 (2.9,3.4)
Sleep disturbance score 14.4 (12.4, 16.5) 14.5 (14.0, 15.0) 3.9 (3.6, 4.2) 11.2 (10.7, 11.6)
FM research criteria (and components)
Proportion positive (%) 53% 54% 4% 16%
Widespread pain index 7.2 (6.0, 8.5) 7.4 (7.0, 7.8) 2.9 (2.7, 3.2) 5.0 (4.7, 5.3)
Symptom severity score 7.9 (6.9, 8.9) 8.4 (8.2, 8.7) 2.7 (2.5, 2.9) 5.4 (5.2, 5.6)
Macfarlane et al. BMC Rheumatology            (2020) 3:19 Page 4 of 11
all domains and consequently had average WPI scores
lower by between 1.3–1.5 and SSS lower by between
2.0–2.2.
Examining factors which were not used in the cluster-
ing of fibromyalgia patients (Table 4) Clusters 1 and 2
were very similar with respect to almost all the charac-
teristics examined although Cluster 1 had primarily fe-
male members and members who were less likely to
have recent use of DMARDs. Cluster 3 had better dis-
ease activity, although all three fibromyalgia patient clus-
ters had ASDAS scores in the “very high disease activity”
range. Cluster 3 also had better function, physical and
particularly mental health, quality of life and work
parameters.
Discussion
We have found evidence of distinct groups of axSpA pa-
tients: those with high disease activity which is either
mainly axial or (in a smaller group) both axial and per-
ipheral and in whom more than half of persons meet cri-
teria for fibromyalgia; patients with low disease activity
(in whom the prevalence of fibromyalgia is similar to
persons without axial spondyloarthritis); and a group of
patients with intermediate disease activity but with high
levels of sleep disturbance and a raised prevalence of
fibromyalgia. Within patients who meet criteria for
fibromyalgia, there are two groups with higher axSpA
disease activity (one with primarily axial disease and a
smaller group with axial and peripheral disease) and this
is reflected in higher pain and symptom severity scores
of the fibromyalgia research criteria, in comparison to a
third group.
The strength of this study was that it used a large na-
tional register to which most patients with axial spondy-
loarthritis were eligible to be enrolled. In examining
clusters it used a split sample approach for their
development and validation. It found consistent results
– there were similar clusters within the total axSpA par-
ticipant group and the sub-group who met research cri-
teria for fibromyalgia. The clusters within the population
group exhibited proportions meeting the research cri-
teria for fibromyalgia which varied from the norm in the
general population (~ 2–5%) ( [21] to two groups with a
prevalence of more than 50%. There are some methodo-
logical issues to be considered in the interpretation.
Ideally the cluster structure should be confirmed in an
external dataset. Not all patients with axSpA meeting
ASAS criteria were eligible to join the register – those
patients who had already commenced biologic therapy
or had previous experience of biologic therapy were not
eligible to be enrolled. The overall proportion of biologic
therapy patients recruited was 7% lower than the pro-
portion reporting taking biologic therapy in a recent sur-
vey of 1979 members of the National Ankylosing
Spondylitis Society – the UK patient support group
(36% v. 43%) [22]. The relative size of the clusters should
be considered indicative, therefore. This is particularly
true with respect to patients who meet only the clinical
arm of the ASAS criteria. They were only eligible for the
registry in the latter 3 years of the 5-year recruitment
period. We therefore examined the relative sizes of the
clusters if only this latter period was considered. For all
patients the distribution (for 1000 nominal patients)
changed from 25:274:337:364 across Clusters 1–4 to
25:296:302:377 and for FM patients from 58:534:408
across Clusters 1–3 to 62:541:397. Thus it can be seen
that the relatively sizes of the clusters are changed very
little when we consider only the period over which pa-
tients meeting the clinical criteria of ASAS were eligible.
The second methodological issue is that the patient
data used in this study varied with respect to their entry
into the study. Some patients who were enrolled later in
Fig. 1 Cluster solutions within whole BSRBR-AS population
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Table 2 Differences in clinical and patient reported characteristics (not used in clustering) across clusters (total population)
Cluster 1 Cluster 2 Cluster 3 Cluster 4 p value
N (%) N (%) N (%) N (%)
Categorical variable
Gender
male 13 (40.6) 209 (60.2) 297 (69.6) 298 (64.5) p < 0.001
female 19 (59.4) 138 (39.8) 130 (30.4) 164 (35.5)
Smoking Status
never 10 (31.2) 129 (37.6) 201 (47.4) 214 (46.8) p < 0.001
ex 14 (43.8) 116 (33.8) 168 (39.6) 180 (39.4)
current 8 (25.0) 98 (28.6) 55 (13.0) 63 (13.8)
Alcohol Use
never 1 (3.1) 39 (11.4) 20 (4.7) 25 (5.5) p < 0.001
ex 9 (28.1) 94 (27.5) 41 (9.7) 63 (13.9)
current 22 (68.8) 209 (61.1) 361 (85.6) 366 (80.6)
Employed
no 15(46.9) 164 (47.3) 113 (26.5) 160 (34.9)* p < 0.001
yes 17 (53.1) 183 (52.7) 314 (73.5) 299 (65.1)
Job type
mainly sedentary 8 (50.0) 81 (45.5) 171 (56.1) 179 (61.5) p = 0.009
mainly physical 8 (50.0) 97 (54.5) 134 (43.9) 112 (38.5)
Current biologic therapy
no 22 (68.8) 211 (61.0) 364 (86.3) 350 (76.1)* p < 0.001
yes 10 (31.2) 135 (39.0) 58 (13.7) 110 (23.9)
NSAID (last 6 m)
no 7 (21.9) 114 (32.9) 136 (31.9) 142 (30.7) p = 0.611
yes 25 (78.1) 233 (67.1) 291 (68.1) 320 (69.3)
DMARD use in past 6 m
no 21 (65.6) 305 (87.9) 374 (87.6) 401 (86.8) p = 0.004
yes 11 (34.4) 42 (12.1) 53 (12.4) 61 (13.2)
HLA B27 status
positive 20 (62.5) 148 (42.7) 260 (60.9) 242 (52.4)* p < 0.001
negative 7 (21.9) 58 (16.7) 52 (12.2) 66 (14.3)
untested 5 (15.6) 141 (40.6) 115 (26.9) 154 (33.3)
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Age
years 49.5 (45.2, 53.8) 47.5 (46.0, 48.9) 49.4 (48.1, 50.7) 50.3 (48.9, 51.6) p = 0.062
Age at symptom onset
years 31.7 (27.7, 35.7) 30.7 (29.3, 32.0) 28.8 (27.8, 29.8) 29.7 (28.6, 30.8) p = 0.074
Disease Activity
BASDAI: 0 (best) – 10 (worst) 6.7 (5.9, 7.4) 6.7 (6.5, 6.9) 2.5 (2.3, 2.6) 4.5 (4.3, 4.7)* p < 0.001
Disease Activity
ASDAS Score 3.6 (3.2, 4.0) 3.7 (3.6, 3.8) 2.2 (2.1, 2.3) 2.9 (2.7, 3.0)* p < 0.001
Physical Function
BASFI: 0 (best) – 10 (worst) 6.2 (5.4, 6.9) 6.5 (6.3, 6.8) 2.5 (2.3, 2.7) 4.3 (4.0, 4.5)* p < 0.001
Spinal Mobility
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the recruitment period would have completed the fibro-
myalgia criteria at baseline or at one of the first
follow-ups while for those recruited early it may have
been up to 2.5 years before they completed their fibro-
myalgia assessment. Thus for the biologic therapy group,
they will have completed this at various points in their
history of such therapy. Finally the 2011 research criteria
for fibromyalgia have not specifically been validated in
the context of inflammatory arthritis. Indeed the criteria
as published exclude persons if their pain could be ex-
plained by another condition. However almost all studies
which have implemented the 2011 research criteria have
dropped this question as it is considered difficult to
evaluate and indeed it has been removed from the 2016
revision of the criteria [23]. We note however that in the
cluster analysis of all axSpA patients, most of the axSpA
patients with high swollen and tender joint count were
in Cluster 1, and that cluster has a very high prevalence
Table 2 Differences in clinical and patient reported characteristics (not used in clustering) across clusters (total population)
(Continued)
BASMI: 0 (best) – 10 (worst) 4.2 (3.6, 4.8) 4.1 (3.8, 4.3) 3.4 (3.2, 3.6) 3.7 (3.4, 3.9) p < 0.001
Patient Global
BASG: 0 (best) – 10 (worst) 6.9 (6.2, 7.5) 7.0 (6.8, 7.2) 2.6 (2.4, 2.8) 4.6 (4.3, 4.8)* p < 0.001
Spinal Pain
VAS: 0 (best) – 10 (worst) 5.1 (4.1, 6.2) 6.3 (6.1, 6.6) 2.2 (2.0, 2.4) 4.0 (3.7, 4.2)* p < 0.001
SF12 Mental Component
100 (best) – 0 (worst) 37.6 (33.0, 42.1) 35.2 (34.3, 36.1) 54.0 (53.3, 54.6) 47.2 (46.3, 48.0)* p < 0.001
SF12 Physical Component
100 (best) – 0 (worst) 32.3 (29.3, 35.3) 32.3 (31.2, 33.4) 46.2 (45.3, 47.1) 39.4 (38.4, 40.5)* p < 0.001
Quality of Life
ASQoL: 0 (best) – 18 (worst)) 12.9 (11.3, 14.4) 13.3 (12.9, 13.7) 3.0 (2.7, 3.3) 7.9 (7.5, 8.3)* p < 0.001
Work absence
absenteeism (%) 17.4 (0.1, 34.7) 11.2 (7.7, 14.6) 0.4 (0.1, 0.7) 4.4 (2.6, 6.1)* p < 0.001
Work impairment
presenteeism (%) 48.6 (36.4, 60.7) 52.5 (49.0, 56.1) 15.1 (13.1, 17.0) 28.8 (26.3, 31.4)* p < 0.001
Overall work impairment
(%) 48.8 (35.7, 62.0) 55.1 (51.3, 58.9) 15.4 (13.4, 17.5) 30.4 (27.7, 33.2)* p < 0.001
Other activity impairment
(%) 63.1 (53.8, 72.4) 65.4 (63.1, 67.6) 19.8 (17.9, 21.7) 38.4 (36.1, 40.6)* p < 0.001
*significant difference between cluster 3 & 4 at p < 0.05
Table 3 Clustering variables across clusters and fibromyalgia criteria sub-scale scores (amongst participants who met criteria for
fibromyalgia)
N Cluster 1 Cluster 2 Cluster 3
17 157 120
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Clustering Factors
Extra-spinal manifestation & comorbidity count 3.7 (2.8, 4.6) 1.5 (1.2, 1.7) 1.3 (1.0, 1.5)
Swollen joint count 7.1 (4.2, 10.0) 0.08 (0.002, 0.16) 0.1 (0.01, 0.13)
Tender joint count 15.0 (11.7, 18.3) 0.5 (0.2, 0.8) 0.4 (0.1, 0.7)
Anxiety (HADs - scored 0–21) 12.5 (9.8, 15.1) 13.2 (12.6, 13.7) 8.1 (7.5, 8.7)
Depression (HADs - scored 0–21) 10.8 (8.7, 12.9) 11.2 (10.7, 11.7) 6.2 (5.7, 6.7)
Fatigue (Chalder Fatigue - scored 0–11) 8.9 (7.6, 10.2) 8.5 (8.1, 8.9) 4.6 (4.0, 5.2)
Sleep disturbance (Jenkins - scored 0–20) 18.1 (16.6, 19.6) 16.0 (15.4, 16.6) 10.1 (9.1, 11.1)
FM components
Widespread pain index 9.4 (7.7, 11.0) 9.2 (8.6, 9.8) 7.9 (7.3, 8.4)
Symptom severity score 9.5 (8.6, 10.4) 9.7 (9.4, 10.0) 7.5 (7.2, 7.9)
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Table 4 Differences in clinical and patient reported characteristics (not used in clustering) across clusters (fibromyalgia positive
participants)
Cluster 1 Cluster 2 Cluster 3
N (%) N (%) N (%) p value
Gender
male 4 (23.5) 94 (59.9)a 63 (52.5) p = 0.014
female 13 (76.5) 63 (40.1) 57 (47.5)
Smoking Status
never 5 (29.4) 53 (34.2) 51 (43.6) p = 0.027
ex 6 (35.3) 52 (33.5) 48 (41.0)
current 6 (35.3) 50 (32.3) 18 (15.4)
Alcohol Use
never 1 (5.9) 21 (13.5) 13 (11.1) p = 0.032
ex 7 (41.2) 50 (32.3) 21 (18.0)
current 9 (52.9) 84 (54.2) 83 (70.9)
Employed
no 8 (47.1) 85 (54.1) 47 (39.5) p = 0.054
yes 9 (52.9) 72 (45.9) 72 (60.5)
Job type
mainly sedentary 1 (12.5) 30 (43.5) 39 (55.7) p = 0.044
mainly physical 7 (87.5) 39 (56.5) 31 (44.3)
Current biologic therapy
no 13 (76.5) 87 (55.4) 74 (61.7) p = 0.189
yes 4 (23.5) 70 (44.6) 46 (38.3)
NSAID (last 6 m)
no 3 (17.6) 55 (35.0) 32 (26.7) p = 0.160
yes 14 (82.4) 102 (65.0) 88 (73.3)
DMARD use in past 6 m
no 10 (58.8) 136 (86.6)a 102 (85.0) p = 0.011
yes 7 (41.2) 21 (13.4) 18 (15.0)
Mean 95% CI Mean (95% CI) Mean (95% CI)
Age
years 49.2 (43.3, 55.0) 47.8 (45.7, 50.0) 50.4 (47.8, 53.0) p = 0.445
Age at symptom onset
years 29.3 (25.6, 33.0) 29.7 (27.7, 31.7) 29.7 (27.5, 31.9) p = 0.873
Disease Activity
BASDAI: 0 (best) – 10 (worst) 7.8 (7.2, 8.5) 7.4 (7.2, 7.6) 6.0 (5.7, 6.2) p < 0.001
Disease Activity
ASDAS 3.8 (3.4, 4.2) 3.9 (3.8, 4.1) 3.3 (3.2, 3.5) p < 0.001
Physical Function
BASFI: 0 (best) – 10 (worst) 7.2 (6.3, 8.1) 7.2 (6.9, 7.5) 5.5 (5.1, 5.9) p < 0.001
Spinal Mobility
BASMI: 0 (best) – 10 (worst) 4.3 (3.4, 5.1) 4.2 (3.8, 4.6) 4.1 (3.6, 4.6) p = 0.934
Patient Global
BASG: 0 (best) – 10 (worst) 7.7 (7.1, 8.3) 7.7 (7.4, 7.9) 6.1 (5.7, 6.5) p < 0.001
Spinal Pain
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of fibromyalgia. It is possible that such peripheral in-
volvement may result in high numbers of body regions
scored as painful in the fibromyalgia criteria (although
the influence on abdominal pain and headache aspects
of the criteria is less obvious).
The results of the current study show that inflamma-
tion is strongly associated with meeting criteria for fibro-
myalgia. The clusters with high disease activity all had a
high prevalence of fibromyalgia. Basu et al. [24] have
shown that RA patients who have features of fibromyal-
gia (what they call “fibromyalgianess”), demonstrate
similar neurobiologic features, on imaging, to that ob-
served in fibromyalgia patients. A further study reported
that high levels of inflammation in RA were associated,
on MRI, with more positive connections between the in-
ferior parietal lobule, medial prefrontal cortex, and mul-
tiple brain networks, as well as reduced inferior parietal
lobule grey matter, and that these patterns of connectiv-
ity were associated with reported fatigue, pain and cog-
nitive dysfunction [25]. The authors postulate that such
networks may provide a mechanism by which peripheral
inflammation results in central changes and features typ-
ically associated with fibromyalgia, although to what ex-
tent this association is mediated through emotional
distress remains to be established. When treated with
TNFi therapy, axSpA patients in BSRBR-AS with
co-morbid fibromyalgia showed a similar absolute im-
provement in disease activity and quality of life over 6
months compared to those without co-morbid fibro-
myalgia, and two-thirds no longer satisfied fibromyalgia
criteria suggesting that targeting inflammation is import-
ant to reduce fibromyalgia symptoms in patients with
active axSpA [26].
An alternative explanation is that having fibromyalgia
distorts the measures used to assess axSpA. Indeed,
Alluno et al. [27] demonstrated that measures thought
to be disease specific such as the Bath indices are not
axSpA specific. However it is unlikely that this can en-
tirely account for the current observations. Duffield et
al. [1] in their meta-analysis of chronic inflammatory
arthritis reported that across studies included, patients
with axSpA and fibromyalgia had BASDAI scores that
were around two points higher than those with axSpA
alone (mean difference 2.2 95% CI (1.9, 2.6)). The differ-
ences observed in BASDAI between clusters in our study
greatly exceed such levels. A previous paper from the
BSRBR-AS demonstrated that the presence of co-morbid
fibromyalgia increased BASDAI scores, on average only
by 1.04 (after adjustment for other features of the dis-
ease) and increased the the ASQoL score (indicating
poorer quality of life) by 1.42 [26].
However around one-third of patients with axSpA and
fibromyalgia still have co-morbid fibromyalgia even after
TNFi and those least likely to respond have high scores
on the fibromyalgia symptom severity scale [26]. The re-
tention rate on TNFi at 2 years is also lower for axSpA
patients with co-morbid fibromyalgia (28% v. 42%) [6]. It
seems therefore that even if inflammation is the primary
driver of fibromyalgia symptoms, then once developed,
therapeutic targeting of inflammatory pathways while
important, is not sufficient. Further we have observed in
the cluster results of all axSpA, a group of patients with
modest disease activity and high levels of sleep disturb-
ance who show a high prevalence of fibromyalgia.
Whether additionally using non pharmacologic therapies
(such as cognitive behaviour therapies) improves
Table 4 Differences in clinical and patient reported characteristics (not used in clustering) across clusters (fibromyalgia positive
participants) (Continued)
0 (best) – 10 (worst) 6.2 (4.7, 7.6) 7.1 (6.8, 7.4) 5.6 (5.1, 6.0) p < 0.001
SF12 Mental Component
100 (best) – 0 (worst) 31.4 (26.6, 36.3) 32.5 (31.1, 34.0) 44.2 (42.5, 45.9) p < 0.001
SF12 Physical Component
100 (best) – 0 (worst) 28.9 (25.0, 32.8) 29.9 (28.4, 31.5) 34.3 (32.4, 36.2) p < 0.001
Quality of Life
ASQoL: 0 (best) – 18 (worst) 15.4 (14.2, 16.7) 14.6 (14.1, 15.1) 10.9 (10.2, 11.5) p < 0.001
Work absence
absenteeism: % 7.0 (1.3, 12.7) 14.2 (8.2, 20.1) 9.3 (4.4, 14.1) p = 0.737
Work impairment
presenteeism: % 55.6 (42.4, 68.7) 60.3 (55.1, 65.6) 44.8 (39.8, 49.8) p < 0.001
Overall work impairment
% 56.4 (41.3, 71.6) 63.4 (58.0, 68.9) 48.0 (42.7, 53.3) p < 0.001
Other activity impairment
% 75.9 (66.4, 85.4) 72.0 (69.4, 74.7) 54.5 (50.2, 58.8) p < 0.001
asignificant difference between cluster 1 & 2 at p < 0.05
Macfarlane et al. BMC Rheumatology            (2020) 3:19 Page 9 of 11
outcomes in such patient groups is not known but evi-
dence in relation to pain (including fibromyalgia) and
sleep disorders is promising [28, 29] and is currently be-
ing evaluated in ongoing studies of patients with axSpA
and fibromyalgia.
Conclusions
In summary, this analysis has demonstrated distinct
groups of axSpA patients with very different likelihood
of reporting co-morbid fibromyalgia. The major feature
defining clusters with a high prevalence of fibromyalgia
is high disease activity and taken together with evidence
from previous studies in this population, and others,
managing the co-morbid fibromyalgia may be most suc-
cessful with pharmacologic therapy to target inflamma-
tion but enhanced by the concurrent use of
non-pharmacologic therapy. This hypothesis awaits test-
ing in formal studies. However the recording of informa-
tion on features of fibromyalgia is not routine in most
clinics assessing axSpA – and it would be important, if
we seek to provide appropriate approaches to manage-
ment to firstly ensure we are collecting relevant informa-
tion to identify such disease features.
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